Provided is a method of activating gene expression using a protein having 90% or more sequence identity to SEQ ID NO:45. The protein activates the expression of a gene upon induction with a medium-chain or long-chain alkane or a medium-chain or long-chain fatty acid methyl ester. Also provided is a whole-cell catalytic system regulated by a medium-chain or long-chain alkane or a medium-chain or long-chain fatty acid methyl ester. The system includes a recombinant microbial cell expressing the protein and an alkane monooxygenase. Also provided is a method of preparing a medium-chain or long-chain alkane terminal oxidation product using the whole-cell catalytic system.

The disclosure provides methods for treating or preventing coronavirus infection comprising administration of a therapeutically effective amount of lactoferrin or a therapeutically effective amount of a protein fusion comprising recombinant lactoferrin fused to the receptor binding domain of the SARS-CoV-2 spike protein. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin.

The disclosure provides methods for treating or preventing coronavirus infection comprising administration of a therapeutically effective amount of lactoferrin or a therapeutically effective amount of a protein fusion comprising recombinant lactoferrin fused to the receptor binding domain of the SARS-CoV-2 spike protein. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).

Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).

A method of treating Type 2 diabetes (T2D) is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes an insulin-transferrin fusion protein or its prodrug, proinsulin-transferrin fusion protein.

A method of treating Type 2 diabetes (T2D) is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes an insulin-transferrin fusion protein or its prodrug, proinsulin-transferrin fusion protein.

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.